it all depends on whether they can secure other deals with big pharma. the one with nvo, assuming nvo gets approval, could bring in $100+ million in royalty revenue to EMIS alone. add that to other potential deals, the price target could be crazy high $20-$30+ but again, management is horrific so you never know.
News 
Market Data 
Discover 
